Cargando…

Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020

BACKGROUND: We conducted a single-center cohort study of rheumatoid arthritis (RA) patients from 2011 to 2020 to understand their real world treatment and outcomes, especially changes in physical function and quality of life (QOL) in elderly patients, including those aged ≥ 80 years. METHODS: For RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Wataru, Kadoya, Masatoshi, Omoto, Atsushi, Yanagida, Takuya, Isoda, Yu, Sunaga, Atsuhiko, Kusuoka, Hiroaki, Ueno, Kentaro, Morita, Satoshi, Kohno, Masataka, Kawahito, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361625/
https://www.ncbi.nlm.nih.gov/pubmed/35945556
http://dx.doi.org/10.1186/s13075-022-02883-x
_version_ 1784764567473094656
author Fukuda, Wataru
Kadoya, Masatoshi
Omoto, Atsushi
Yanagida, Takuya
Isoda, Yu
Sunaga, Atsuhiko
Kusuoka, Hiroaki
Ueno, Kentaro
Morita, Satoshi
Kohno, Masataka
Kawahito, Yutaka
author_facet Fukuda, Wataru
Kadoya, Masatoshi
Omoto, Atsushi
Yanagida, Takuya
Isoda, Yu
Sunaga, Atsuhiko
Kusuoka, Hiroaki
Ueno, Kentaro
Morita, Satoshi
Kohno, Masataka
Kawahito, Yutaka
author_sort Fukuda, Wataru
collection PubMed
description BACKGROUND: We conducted a single-center cohort study of rheumatoid arthritis (RA) patients from 2011 to 2020 to understand their real world treatment and outcomes, especially changes in physical function and quality of life (QOL) in elderly patients, including those aged ≥ 80 years. METHODS: For RA patients attending our outpatient clinic, we annually recorded tender and swollen joint counts, laboratory findings, therapeutic drugs, and scores from the Japanese Health Assessment Questionnaire and EuroQoL-5 Dimensions questionnaire. We examined changes in treatment and outcomes over time, by age group, in patients enrolled over a 10-year period, from 2011 to 2020. RESULTS: One thousand eight hundred thirty RA patients were enrolled and data were recorded once a year, and a total of 9299 patient records were evaluated. The average age of patients increased by 3.7 years during the study period; the patients aged rapidly. Intensive pharmacological treatment was more frequent in younger patients. Disease activity, physical function, and QOL showed improvement in all age groups over the study period. Physical function and QOL showed greater changes with aging, compared with disease activity. This may be due to the effects of accumulated RA damage, disability due to aging, and depression. CONCLUSIONS: Intensive pharmacological treatment contributes to not only control of disease activity but also the improvement of physical activity and QOL, even in elderly patients. Relieving age-related physical impairment and depression may improve the QOL of very elderly RA patients.
format Online
Article
Text
id pubmed-9361625
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93616252022-08-10 Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020 Fukuda, Wataru Kadoya, Masatoshi Omoto, Atsushi Yanagida, Takuya Isoda, Yu Sunaga, Atsuhiko Kusuoka, Hiroaki Ueno, Kentaro Morita, Satoshi Kohno, Masataka Kawahito, Yutaka Arthritis Res Ther Research BACKGROUND: We conducted a single-center cohort study of rheumatoid arthritis (RA) patients from 2011 to 2020 to understand their real world treatment and outcomes, especially changes in physical function and quality of life (QOL) in elderly patients, including those aged ≥ 80 years. METHODS: For RA patients attending our outpatient clinic, we annually recorded tender and swollen joint counts, laboratory findings, therapeutic drugs, and scores from the Japanese Health Assessment Questionnaire and EuroQoL-5 Dimensions questionnaire. We examined changes in treatment and outcomes over time, by age group, in patients enrolled over a 10-year period, from 2011 to 2020. RESULTS: One thousand eight hundred thirty RA patients were enrolled and data were recorded once a year, and a total of 9299 patient records were evaluated. The average age of patients increased by 3.7 years during the study period; the patients aged rapidly. Intensive pharmacological treatment was more frequent in younger patients. Disease activity, physical function, and QOL showed improvement in all age groups over the study period. Physical function and QOL showed greater changes with aging, compared with disease activity. This may be due to the effects of accumulated RA damage, disability due to aging, and depression. CONCLUSIONS: Intensive pharmacological treatment contributes to not only control of disease activity but also the improvement of physical activity and QOL, even in elderly patients. Relieving age-related physical impairment and depression may improve the QOL of very elderly RA patients. BioMed Central 2022-08-09 2022 /pmc/articles/PMC9361625/ /pubmed/35945556 http://dx.doi.org/10.1186/s13075-022-02883-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fukuda, Wataru
Kadoya, Masatoshi
Omoto, Atsushi
Yanagida, Takuya
Isoda, Yu
Sunaga, Atsuhiko
Kusuoka, Hiroaki
Ueno, Kentaro
Morita, Satoshi
Kohno, Masataka
Kawahito, Yutaka
Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020
title Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020
title_full Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020
title_fullStr Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020
title_full_unstemmed Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020
title_short Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020
title_sort treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in japan from 2011 to 2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361625/
https://www.ncbi.nlm.nih.gov/pubmed/35945556
http://dx.doi.org/10.1186/s13075-022-02883-x
work_keys_str_mv AT fukudawataru treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT kadoyamasatoshi treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT omotoatsushi treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT yanagidatakuya treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT isodayu treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT sunagaatsuhiko treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT kusuokahiroaki treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT uenokentaro treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT moritasatoshi treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT kohnomasataka treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020
AT kawahitoyutaka treatmentofrheumatoidarthritisanditsoutcomesinanagingsocietyasinglecentercohortstudyinjapanfrom2011to2020